3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Dexamethasone
20
Melphalan
13
Thalidomide
10
Bortezomib
10
Lenalidomide
8
Cyclophosphamide
8
Prednisone
6
Filgrastim
6
Doxorubicin
6
Vincristine
5
Epoetin Alfa
5
pomalidomide
3
Zoledronic Acid
3
Peripheral Blood Stem Cell Transplantation
3
Idarubicin
3
carfilzomib
2
Vorinostat
2
Radiotherapy
2
Interferon-alpha
2
Granulocyte Colony-Stimulating Factor
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Carmustine
2
Calcium Dobesilate
2
Busulfan
2
valspodar
1
sargramostim
1
oblimersen
1
liposomal doxorubicin
1
isatuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Plasma Cell
×
Panobinostat
×
Clear all
NCT01023308
2020-03-17
PANORAMA-1
Novartis
Phase 3
Completed
767 enrolled
17 charts